Silence Therapeutics PLC Market Cap ($842.19 Million)
Market Cap & Net Worth: Silence Therapeutics PLC (SLN)
Silence Therapeutics PLC market cap. Silence Therapeutics PLC (NASDAQ:SLN) has a market capitalization of $842.19 Million ($842.19 Million) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9277 globally and #2631 in its home market, demonstrating a 0.46% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Silence Therapeutics PLC's stock price $19.75 by its total outstanding shares 62154086 (62.15 Million). Also see Silence Therapeutics PLC cash conversion from operations for how efficiently the company converts equity into cash flow.
Silence Therapeutics PLC Market Cap History (2020–2026)
Silence Therapeutics PLC market cap history from 2020 to 2026. Data shows growth from $1.37 Billion to $1.23 Billion (0.21% CAGR). Check SLN share price today for real-time trading data and today's change.
Index Memberships
Silence Therapeutics PLC is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.03% | #269 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #997 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.05% | #157 of 263 |
Weight: Silence Therapeutics PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Silence Therapeutics PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Silence Therapeutics PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore SLN net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
676.02x
Silence Therapeutics PLC's market cap is 676.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.37 Billion | $5.48 Million | -$32.55 Million | 249.57x | N/A |
| 2021 | $1.48 Billion | $12.41 Million | -$39.41 Million | 119.60x | N/A |
| 2022 | $947.85 Million | $17.65 Million | -$41.03 Million | 53.69x | N/A |
| 2023 | $1.08 Billion | $25.38 Million | -$43.27 Million | 42.55x | N/A |
| 2024 | $427.62 Million | $43.26 Million | -$45.31 Million | 9.89x | N/A |
| 2025 | $377.90 Million | $559.00K | -$88.61 Million | 676.02x | N/A |
Competitor Companies of SLN by Market Capitalization
Companies near Silence Therapeutics PLC in the global market cap rankings as of November 1, 2026. Also see SLN total assets for a full breakdown of the balance sheet.
Key companies related to Silence Therapeutics PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Silence Therapeutics PLC (2020–2026)
Market capitalization of Silence Therapeutics PLC from 2020 to today. Between 2020 and today, Silence Therapeutics PLC's market cap moved from $1.37 Billion to $ 1.23 Billion, with a yearly change of 0.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.23 Billion | +224.84% |
| 2025 | $377.90 Million | -11.63% |
| 2024 | $427.62 Million | -60.39% |
| 2023 | $1.08 Billion | +13.90% |
| 2022 | $947.85 Million | -36.17% |
| 2021 | $1.48 Billion | +8.59% |
| 2020 | $1.37 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Silence Therapeutics PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $842.19 Million USD |
| MoneyControl | $842.19 Million USD |
| MarketWatch | $842.19 Million USD |
| marketcap.company | $842.19 Million USD |
| Reuters | $842.19 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Silence Therapeutics PLC
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated… Read more